Related Experiment Video

Updated: Aug 9, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Cellular pharmacology of DUP-785, a new anticancer agent

L W Anderson1, J M Strong, R L Cysyk

  • 1Laboratory of Biological Chemistry, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Cancer Communications
|January 1, 1989
PubMed

Insights

DUP-785 inhibits dihydroorotate dehydrogenase, impacting de novo pyrimidine synthesis in L1210 cancer cells. Prolonged exposure shows cell proliferation decoupling from pyrimidine synthesis recovery, indicating sustained anticancer effects.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cancer Biology

Background:

  • Dihydroorotate dehydrogenase (DHODH) is crucial for de novo pyrimidine synthesis.
  • DUP-785 is a novel DHODH inhibitor investigated for anticancer properties.
  • Understanding the impact of DUP-785 on pyrimidine metabolism and cell proliferation is essential.

Purpose of the Study:

  • To quantify dihydroorotate accumulation in L1210 cells treated with DUP-785.
  • To investigate the relationship between DUP-785-induced inhibition of pyrimidine synthesis and cell proliferation.
  • To determine the duration of DUP-785's effects on pyrimidine nucleotide pools and cell growth.

Main Methods:

  • Gas chromatography-mass spectrometry (GC/MS) for dihydroorotate quantification.
  • Culturing L1210 cells with varying concentrations and durations of DUP-785 exposure.
  • Monitoring cell proliferation via cloning efficiency and pyrimidine nucleotide concentrations.

Main Results:

  • A GC/MS method was established to measure dihydroorotate.
  • Short-term DUP-785 exposure showed direct correlations between pyrimidine synthesis inhibition, nucleotide levels, and proliferation.
  • Prolonged exposure (>24 hr) revealed a dissociation: pyrimidine synthesis recovered, but cell proliferation remained inhibited.
  • Maximum cell kill (99.9%) was achieved at 24 hr, with no further increase up to 96 hr.

Conclusions:

  • DUP-785 effectively inhibits de novo pyrimidine synthesis in L1210 cells.
  • Prolonged DUP-785 treatment leads to sustained inhibition of cell proliferation, independent of pyrimidine synthesis recovery.
  • These findings support DUP-785's potential as an anticancer agent with lasting effects.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...